Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

Jill Hibishman Samis*, Paul Lee, Donald Zimmerman, Robert J. Arceci, Meinolf Suttorp, Nobuko Hijiya

*Corresponding author for this work

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.

Original languageEnglish (US)
Pages (from-to)1332-1338
Number of pages7
JournalPediatric Blood and Cancer
Volume63
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Pediatrics
Puberty
Life Expectancy
Fertility
Thyroid Gland
Therapeutics
Bone and Bones
Growth
Population

Keywords

  • children
  • CML
  • endocrine
  • growth
  • TKI

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{ee9f6a72a5fd4c0cb7b74ce7fbca845d,
title = "Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia",
abstract = "Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.",
keywords = "children, CML, endocrine, growth, TKI",
author = "Samis, {Jill Hibishman} and Paul Lee and Donald Zimmerman and Arceci, {Robert J.} and Meinolf Suttorp and Nobuko Hijiya",
year = "2016",
month = "8",
day = "1",
doi = "10.1002/pbc.26028",
language = "English (US)",
volume = "63",
pages = "1332--1338",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "8",

}

Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia. / Samis, Jill Hibishman; Lee, Paul; Zimmerman, Donald; Arceci, Robert J.; Suttorp, Meinolf; Hijiya, Nobuko.

In: Pediatric Blood and Cancer, Vol. 63, No. 8, 01.08.2016, p. 1332-1338.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia

AU - Samis, Jill Hibishman

AU - Lee, Paul

AU - Zimmerman, Donald

AU - Arceci, Robert J.

AU - Suttorp, Meinolf

AU - Hijiya, Nobuko

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.

AB - Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to “off-target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.

KW - children

KW - CML

KW - endocrine

KW - growth

KW - TKI

UR - http://www.scopus.com/inward/record.url?scp=84976474984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976474984&partnerID=8YFLogxK

U2 - 10.1002/pbc.26028

DO - 10.1002/pbc.26028

M3 - Review article

C2 - 27100618

AN - SCOPUS:84976474984

VL - 63

SP - 1332

EP - 1338

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 8

ER -